These results demonstrate that CXCR2+ MDSCs can accelerate breast tumor growth and metastasis via directly inducing cancer cells EMT and indirectly promoting T cells exhaustion, suggesting that CXCR2+ MDSCs may be a potential target for breast cancer therapy. Here, CXCR2 is linked to cancer.